United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human Lactoferrin ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Lactotransferrin, Talactoferrin, LTF, GIG12, HEL110, HLF2, LF, Lactotransferrin, rowth inhibiting protein 12
  • Species:Human
Cat. No. Size Price

RHK329-01R 96 wells (1 kit) $785
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Stool, Urine, Milk, Plasma, Cell culture supernatant

Sample Requirements

10 µl/well


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0.4-100 ng/ml

Limit of Detection

0.4 ng/ml



The total assay time is 4.5 hours

The kit measures Lactoferrin in human Plasma, Urine, Stool, Milk, Cell Culture Supernatant

Assay format is 96 wells

Components of the kit are provided ready to use or concentrated

Research topic

Bone and cartilage metabolism, Energy metabolism and body weight regulation, Immune Response, Infection and Inflammation, Inflammatory bowel disease, Iron metabolism, Lipoprotein metabolism, Oncology


Human lactoferrin (LF) is an 80 kDa glycoprotein found concentrated in the secondary granules of the neutrophils. In addition, lactoferrin can be found in epithelia and most body fluids and secretions. Lactoferrin was first isolated from human milk and plays an important part in the immune system by helping to fight infections. It has the ability to bind iron and possesses five different enzyme activities: DNase, RNase, ATPase, phosphatase, and malto-oligosaccharide hydrolysis. Lactoferrin is a natural anti-bacterial, anti-fungal and anti-viral protein, it is an antioxidant and also possesses immunomodulatory properties. Furthermore, lactoferrin promotes the health of the gastro-intestinal system by improving the intestinal microbalance. Lactoferrin is secreted in plasma by neutrophils. Plasma of healthy individuals contains ~190-500 ng/ml LF. The lactoferrin plasma concentration represents a positive relation to the total pool of neutrophils and the rate of neutrophil turnover. Upon inflammation, lactoferrin is released from the secondary neutrophil granules into the extracellular medium. Therefore, the extracellular lactoferrin concentration can be used as an index for neutrophil activation. The iron binding property of lactoferrin is considered to be an important antimicrobial function. Human lactoferrin binds via its highly positively charged amino-terminus to bacterial products. It kills various bacteria, most probably by inducing intracellular changes in these bacteria without affecting the membrane permeability. Cleavage by pepsin of lactoferrin leads to the release of lactoferricin H. This 47amino acid peptide has more antimicrobial activity than its precursor and it can inhibit the classical but not the alternative complement pathway. Urine or breast milk of healthy persons contain ~30 ng/ml and ~500 µg/ml LF, respectively. During infection, the LF concentration can raise 10-100-fold. In feces of healthy persons, ~1 µg/g LF can be detected, whereas in feces derived from colon cancer or inflammatory bowel disease (IBD) patients, LF levels range from ~75-310 µg/g. Faecal lactoferrin is useful as a sensitive and specific marker in identifying intestinal inflammation such as Crohn’s disease and IBD. Combination of several markers, such as calprotectin, defensin, elastase, MPO, I-FABP and MAdCAM, may be useful for classifying IBD, as well as for identifying tumor grade and to confirm remission/response to treatment. Therefore, the human lactoferrin ELISA is a sensitive, non-invasive tool for monitoring disease activity.

Summary References (26)

References to Lactoferrin

  • Abrink M, Larsson E, Gobl A, Hellman L. Expression of lactoferrin in the kidney: implications for innate immunity and iron metabolism. Kidney Int. 2000 May;57 (5):2004-10
  • Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des. 2009;15 (17):1956-73
  • Aisen P, Leibman A. Lactoferrin and transferrin: a comparative study. Biochim Biophys Acta. 1972 Feb 29;257 (2):314-23
  • Antonsen S, Wiggers P, Dalhoj J, Blaabjerg O. An enzyme-linked immunosorbent assay for plasma-lactoferrin. Concentrations in 362 healthy, adult blood donors. Scand J Clin Lab Invest. 1993 Apr;53 (2):133-44
  • Baynes RD, Bezwoda WR. Lactoferrin and the inflammatory response. Adv Exp Med Biol. 1994;357:133-41
  • Bennett RM, Mohla C. A solid-phase radioimmunoassay for the measurement of lactoferrin in human plasma: variations with age, sex, and disease. J Lab Clin Med. 1976 Jul;88 (1):156-66
  • Bezault J, Bhimani R, Wiprovnick J, Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 1994 May 1;54 (9):2310-2
  • Birgens HS. Lactoferrin in plasma measured by an ELISA technique: evidence that plasma lactoferrin is an indicator of neutrophil turnover and bone marrow activity in acute leukaemia. Scand J Haematol. 1985 Apr;34 (4):326-31
  • Boxer LA, Coates TD, Haak RA, Wolach JB, Hoffstein S, Baehner RL. Lactoferrin deficiency associated with altered granulocyte function. N Engl J Med. 1982 Aug 12;307 (7):404-10
  • Brock JH. Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the newborn infant. Arch Dis Child. 1980 Jun;55 (6):417-21
  • Brock JH. The physiology of lactoferrin. Biochem Cell Biol. 2002;80 (1):1-6
  • Devi AS, Das MR, Pandit MW. Lactoferrin contains structural motifs of ribonuclease. Biochim Biophys Acta. 1994 Apr 13;1205 (2):275-81
  • Gonzalez-Chavez SA, Arevalo-Gallegos S, Rascon-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents. 2009 Apr;33 (4):301.e1-8
  • Jenssen H, Hancock RE. Antimicrobial properties of lactoferrin. Biochimie. 2009 Jan;91 (1):19-29
  • Kanyshkova TG, Buneva VN, Nevinsky GA. Lactoferrin and its biological functions. Biochemistry (Mosc). 2001 Jan;66 (1):1-7
  • Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci. 2005 Nov;62 (22):2549-59
  • Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica. 1995 May-Jun;80 (3):252-67
  • Naot D, Grey A, Reid IR, Cornish J. Lactoferrin--a novel bone growth factor. Clin Med Res. 2005 May;3 (2):93-101
  • Niemela A, Kulomaa M, Vija P, Tuohimaa P, Saarikoski S. Lactoferrin in human amniotic fluid. Hum Reprod. 1989 Jan;4 (1):99-101
  • Ono T, Murakoshi M, Suzuki N, Iida N, Ohdera M, Iigo M, Yoshida T, Sugiyama K, Nishino H. Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr. 2010 Dec;104 (11):1688-95
  • Steijns JM, van Hooijdonk AC. Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. Br J Nutr. 2000 Nov;84 Suppl 1:S11-7
  • Suzuki YA, Lonnerdal B. Characterization of mammalian receptors for lactoferrin. Biochem Cell Biol. 2002;80 (1):75-80
  • Takeuchi T, Shimizu H, Ando K, Harada E. Bovine lactoferrin reduces plasma triacylglycerol and NEFA accompanied by decreased hepatic cholesterol and triacylglycerol contents in rodents. Br J Nutr. 2004 Apr;91 (4):533-8
  • Tamano S, Sekine K, Takase M, Yamauchi K, Iigo M, Tsuda H. Lack of chronic oral toxicity of chemopreventive bovine lactoferrin in F344/DuCrj rats. Asian Pac J Cancer Prev. 2008 Apr-Jun;9 (2):313-6
  • Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci. 2005 Nov;62 (22):2576-87
  • Ward PP, Paz E, Conneely OM.
Related Products Docs